ASCO 2022 Conference Coverage

 

Breast
54

ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 Adjuvant Abemaciclib for High-risk Early Breast Cancer: Factors Increasing the Rate of Treatment Discontinuations in monarchE

FEATURING Sara Tolaney
  • 52 views
  • July 26, 2022
07:17

ASCO 2022 Conference Coverage

ASCO 2022 Adjuvant Abemaciclib for High-Risk Early Breast Cancer: Factors Increasing the Rate of Treatment Discontinuations in monarchE

FEATURING Sara Tolaney
  • 397 views
  • July 26, 2022
  • 1
01:10

ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 A Phase 1b/2 Study of the BET Inhibitor ZEN-3694 in Combination With Talazoparib for Treatment of Patients With TNBC Without gBRCA1/2 Mutations

FEATURING Philippe Aftimos
  • 21 views
  • July 26, 2022
10:53

ASCO 2022 Conference Coverage

ASCO 2022 A Phase 1b/2 Study of the BET Inhibitor ZEN-3694 in Combination With Talazoparib for Treatment of Patients With TNBC Without gBRCA1/2 Mutations

FEATURING Philippe Aftimos
  • 37 views
  • July 26, 2022
  • 1
10:23

ASCO 2022 Conference Coverage

ASCO 2022 Phase 2 Study of Lasofoxifene + Abemaciclib for Treating Pre-/Post-Menopausal Women With Locally Advanced/Metastatic ER+/HER2- BC and an ESR1 Mutation After Progression on Prior Therapies

FEATURING Senthil Damodaran
  • 271 views
  • June 30, 2022
  • 3
10:12

ASCO 2022 Conference Coverage

ASCO 2022 on FLEX - the 30,000 Breast Cancer Transcriptome Project: A Platform for Early BC Research Using Full-Genome Arrays Paired With Clinical Data

FEATURING Cynthia Ma
  • 153 views
  • June 30, 2022
01:04

ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 Phase 2 Study of Lasofoxifene + Abemaciclib for Treating Pre-/Post-Menopausal Women With Locally Advanced/Metastatic ER+/HER2- BC and an ESR1 Mutation After Progression on Prior Therapies

FEATURING Senthil Damodaran
  • 16 views
  • June 30, 2022
52

ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 on FLEX - the 30,000 Breast Cancer Transcriptome Project: A Platform for Early BC Research Using Full-Genome Arrays Paired With Clinical Data

FEATURING Cynthia Ma
  • 11 views
  • June 30, 2022
01:17

ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 on Monitoring and Management of Interstitial Lung Disease/Pneumonitis Among Patients With mBC Treated With Trastuzumab Deruxtecan

FEATURING Bruce Feinberg
  • 21 views
  • June 23, 2022
11:56

ASCO 2022 Conference Coverage

ASCO 2022 on Monitoring and Management of Interstitial Lung Disease/Pneumonitis Among Patients With mBC Treated With Trastuzumab Deruxtecan

FEATURING Bruce Feinberg
  • 337 views
  • June 23, 2022
  • 2
04:01

ASCO 2022 Conference Coverage

ASCO 2022 on Sacituzumab Govitecan vs. Treatment of Physician’s Choice in Previously Treated mTNBC: Final Results From the Phase 3 ASCENT Study

FEATURING Aditya Bardia
  • 657 views
  • June 21, 2022
  • 5
43

ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 on Sacituzumab Govitecan vs. Treatment of Physician’s Choice in Previously Treated mTNBC: Final Results From the Phase 3 ASCENT Study

FEATURING Aditya Bardia
  • 16 views
  • June 21, 2022
09:57

ASCO 2022 Conference Coverage

ASCO 2022 Preliminary Analysis of an Expanded Access Study of the Fixed-Dose Combination of Pertuzumab & Trastuzumab for Subcutaneous Injection for At-Home Administration in HER2+ BC During the COVID-19 Pandemic

FEATURING Chau Dang
  • 198 views
  • June 21, 2022
01:06

ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 Preliminary Analysis of an Expanded Access Study of the Fixed-Dose Combination of Pertuzumab & Trastuzumab for Subcutaneous Injection for At-Home Administration in HER2+ BC During the COVID-19 Pandemic

FEATURING Chau Dang
  • 40 views
  • June 21, 2022
06:19

ASCO 2022 Conference Coverage

ASCO 2022 Phase 2 Study of Response-Guided Neoadjuvant Sacituzumab Govitecan (IMMU-132) in Localized TNBC: Results From the NeoSTAR Trial

FEATURING Laura Spring
  • 143 views
  • June 21, 2022
  • 1
48

ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 Phase 2 Study of Response-Guided Neoadjuvant Sacituzumab Govitecan (IMMU-132) in Localized TNBC: Results From the NeoSTAR Trial

FEATURING Laura Spring
  • 37 views
  • June 21, 2022
  • 1
04:16

ASCO 2022 Conference Coverage

ASCO 2022 Analyses From PALOMA-2: Overall Survival With 1L Palbociclib + Letrozole vs. Placebo + Letrozole in Women With ER+/HER2- ABC

FEATURING Dennis Slamon
  • 1,208 views
  • June 16, 2022
  • 2
03:10

ASCO 2022 Conference Coverage

ASCO 2022 Neoadjuvant HER2-Targeted Therapy +/- Immunotherapy With Pembrolizumab: An Open Label Randomized Phase 2 Trial

FEATURING Heather McArthur
  • 89 views
  • June 16, 2022
04:36

ASCO 2022 Conference Coverage

ASCO 2022 A Single-Arm, Phase 2 Study of Perioperative Ipi, Nivo, and Cryoablation in Women With HER2- Early Stage/Resectable BC

FEATURING Heather McArthur
  • 21 views
  • June 16, 2022
56

ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 Neoadjuvant HER2-Targeted Therapy +/- Immunotherapy With Pembrolizumab: An Open Label Randomized Phase 2 Trial

FEATURING Heather McArthur
  • 11 views
  • June 16, 2022
37

ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 A Single-Arm, Phase 2 Study of Perioperative Ipi, Nivo, and Cryoablation in Women With HER2- Early Stage/Resectable BC

FEATURING Heather McArthur
  • 9 views
  • June 16, 2022
50

ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 on a Randomized Phase II/III PARTNER Trial to Evaluate the Safety & Efficacy of the Addition of Olaparib to Platinum-based Neoadjuvant Chemo in TNBC and/or Germline BRCAm BC

FEATURING Rebecca Lucey
  • 19 views
  • June 16, 2022
05:52

ASCO 2022 Conference Coverage

ASCO 2022 on a Randomized Phase II/III PARTNER Trial to Evaluate the Safety & Efficacy of the Addition of Olaparib to Platinum-Based Neoadjuvant Chemo in TNBC and/or Germline BRCAm BC

FEATURING Rebecca Lucey
  • 119 views
  • June 16, 2022
  • 1
43

ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 Overall Survival With 1L Palbociclib + Letrozole vs. Placebo + Letrozole in Women With ER+/HER2- ABC: Analyses From PALOMA-2

FEATURING Dennis Slamon
  • 24 views
  • June 16, 2022
03:41

ASCO 2022 Conference Coverage

ASCO 2022 Adherence to EndoPredict Test Scores for Extended ET Management in the Prospective EndoPredict Extended Endocrine Trial

FEATURING Adam Brufsky
  • 157 views
  • June 15, 2022
  • 1
47

ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 Adherence to EndoPredict Test Scores for Extended ET Management in the Prospective EndoPredict Extended Endocrine Trial

FEATURING Adam Brufsky
  • 12 views
  • June 15, 2022
01:03

ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 on EFS by Residual Cancer Burden After Neoadjuvant Pembro + Chemo vs. Placebo + Chemo for eTNBC: Exploratory Analysis From the KEYNOTE-522

FEATURING Lajos Pusztai
  • 37 views
  • June 14, 2022
  • 1
13:17

ASCO 2022 Conference Coverage

ASCO 2022 on EFS by Residual Cancer Burden After Neoadjuvant Pembro + Chemo vs. Placebo + Chemo for eTNBC: Exploratory Analysis From the KEYNOTE-522

FEATURING Lajos Pusztai
  • 1,982 views
  • June 14, 2022
  • 10
05:13

ASCO 2022 Conference Coverage

ASCO 2022 Optimization of the Duration of Adjuvant Endocrine Therapy in Early Breast Cancer

FEATURING Barbara Pistilli
  • 39 views
  • June 13, 2022
34

ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 Trastuzumab Deruxtecan vs. Trastuzumab Emtansine in HER2+ Unresectable and/or Metastatic Breast Cancer: Safety Follow-Up of the Phase 3 DESTINY-Breast03

FEATURING Erika Hamilton
  • 413 views
  • June 13, 2022
  • 3
28

ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 Optimization of the Duration of Adjuvant Endocrine Therapy in Early Breast Cancer

FEATURING Barbara Pistilli
  • 27 views
  • June 13, 2022
44

ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 Impact of BMI on Treatment and Outcomes in Patients With HR+ EBC Receiving ET +/- Palbociclib in the PALLAS Trial

FEATURING Georg Pfeiler
  • 16 views
  • June 10, 2022
43

ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 on Alpelisib + Continued ET Following Progression on ET in HR+/HER2-/PIK3CAm mBC: A Big Ten Cancer Research Consortium Study

FEATURING Cristina Truica
  • 65 views
  • June 10, 2022
04:56

ASCO 2022 Conference Coverage

ASCO 2022 Impact of BMI on Treatment and Outcomes in Patients With HR+ EBC Receiving ET +/- Palbociclib in the PALLAS Trial

FEATURING Georg Pfeiler
  • 297 views
  • June 10, 2022
  • 1
06:50

ASCO 2022 Conference Coverage

ASCO 2022 on Alpelisib + Continued ET Following Progression on ET in HR+/HER2-/PIK3CAm mBC: A Big Ten Cancer Research Consortium Study

FEATURING Cristina Truica
  • 303 views
  • June 10, 2022
  • 3
04:28

ASCO 2022 Conference Coverage

ASCO 2022 Subgroup Analysis of Patients With No Prior Chemo in Phase 3 EMERALD Trial: Elacestrant vs. Investigator’s Choice of Endocrine Monotherapy for ER+/HER2 mBC

FEATURING Virginia Kaklamani
  • 286 views
  • June 10, 2022
  • 3
30

ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 Subgroup Analysis of Patients With No Prior Chemo in Phase 3 EMERALD Trial: Elacestrant vs. Investigator’s Choice of Endocrine Monotherapy for ER+/HER2 mBC

FEATURING Virginia Kaklamani
  • 56 views
  • June 10, 2022
01:18

ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 Survival Outcomes in Metastatic HR+, HER2- IDC Compared to ILC and Mixed Ductal/Lobular Treated With ET in Combination With CDK4/6is/mTORi/PI3Ki

FEATURING Jason Mouabbi
  • 17 views
  • June 9, 2022
09:18

ASCO 2022 Conference Coverage

ASCO 2022 Survival Outcomes in Metastatic HR+, HER2- IDC Compared to ILC and Mixed Ductal/Lobular Treated With ET in Combination With CDK4/6is/mTORi/PI3Ki

FEATURING Jason Mouabbi
  • 802 views
  • June 9, 2022
  • 6
31

ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 on NRG-BR007: A Phase III Trial Evaluating De-Escalation of Breast Radiation Following BCS of Stage 1 HR+/HER2-/RS≤18 BC

FEATURING Julia White
  • 22 views
  • June 9, 2022
10:55

ASCO 2022 Conference Coverage

ASCO 2022 on NRG-BR007: A Phase III Trial Evaluating De-Escalation of Breast Radiation Following BCS of Stage 1 HR+/HER2-/RS≤18 BC

FEATURING Julia White
  • 23 views
  • June 9, 2022
01:21

ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 on the Type of ET and DFS in Early HER2+/HR+ BC: Analysis From the Phase III Randomized ShortHER Trial

FEATURING Maria Vittoria Dieci
  • 13 views
  • June 9, 2022
06:57

ASCO 2022 Conference Coverage

ASCO 2022 on the Type of ET and DFS in Early HER2+/HR+ BC: Analysis From the Phase III Randomized ShortHER Trial

FEATURING Maria Vittoria Dieci
  • 101 views
  • June 9, 2022
49

ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022: The ImPrint Immune Signature to Identify Patients With High-Risk eBC Who May Benefit From PD-1 Checkpoint Inhibition in I-SPY2

FEATURING Lorenza Mittempergher
  • 37 views
  • June 8, 2022
11:09

ASCO 2022 Conference Coverage

ASCO 2022: The ImPrint Immune Signature to Identify Patients With High-Risk eBC Who May Benefit From PD-1 Checkpoint Inhibition in I-SPY2

FEATURING Lorenza Mittempergher
  • 263 views
  • June 8, 2022
  • 2
32

ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 on Estradiol Levels in Premenopausal Women With HR+ BC on Ovarian Function Suppression With GnRH Agonists

FEATURING Megan Tesch
  • 40 views
  • June 8, 2022
10:19

ASCO 2022 Conference Coverage

ASCO 2022 on Estradiol Levels in Premenopausal Women With HR+ BC on Ovarian Function Suppression With GnRH Agonists

FEATURING Megan Tesch
  • 2,987 views
  • June 8, 2022
  • 5
01:37

ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 on Characterization of Alpelisib-Associated Hyperglycemia in mBC

FEATURING Sherry Shen
  • 18 views
  • June 8, 2022
06:32

ASCO 2022 Conference Coverage

ASCO 2022 on Characterization of Alpelisib-Associated Hyperglycemia in mBC

FEATURING Sherry Shen
  • 364 views
  • June 8, 2022
  • 1
27

ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 on Disparity Between Ki67 Measurements and Tumor Gene Expression Tests in Hormone-Sensitive EBC From the OPTIMA Preliminary Trial

FEATURING Robert Stein
  • 11 views
  • June 7, 2022
08:04

ASCO 2022 Conference Coverage

ASCO 2022 on OPTIMA Preliminary Trial: Disparity Between Ki67 Measurements and Tumor Gene Expression Tests in Hormone-Sensitive EBC

FEATURING Robert Stein
  • 1,415 views
  • June 7, 2022
  • 2